Compare Global X Robo Global Robotics & Automation ETF (ROBO) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robo Global Robotics & Automation ETF vs Twist Bioscience Corp — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $84.94, while Twist Bioscience Corp trades at $126 (market cap $7.86B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, Global X Robo Global Robotics & Automation ETF nearer its low. Which is the better fit depends on your goals.
| ROBO | TWST | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $125.21 |
52-Week Low | $62.34 | $24.16 |
Market Cap | — | $7.86B |
Enterprise Value | — | $7.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ROBO Global Robotics & Automation ETF trades at $84.76, up 0.9% with strong bullish technical signals from moving averages. The robotics sector shows broadening demand for physical AI applications, with recent earnings indicating growth beyond traditional manufacturing. While RSI levels suggest potential overbought conditions, the overall technical outlook remains positive with institutional interest in robotics infrastructure plays.
The robotics ETF benefits from AI infrastructure expansion and industrial automation trends, though valuation metrics remain undisclosed. Key risks include cyclical exposure and competition from newer thematic funds. Analyst sentiment appears cautiously optimistic given the sector's positioning in the AI value chain beyond semiconductors.
Twist Bioscience (TWST) trades at $125.16, up 1.66% today, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth is strong, with Q3 2026 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights a $300 million public offering and expansion in AI-driven drug discovery, fueling investor optimism.
The outlook is mixed: robust revenue growth and analyst buy ratings (78.57%) support upside, but persistent losses, high valuations (P/S of 17.73), and cash flow deficits pose risks. Investors should weigh the potential for EBITDA breakeven by fiscal 2027 against execution challenges in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
